TARA
Protara Therapeutics, Inc.
Set alert
2.48 USD -0.04 -1.59%
2.43 Day range 2.57
2.32 52-week range 7.56
- YTD
- -53.47%
- 1 year
- -51.75%
- Open
- 2.55
- Prev close
- 2.52
- Mkt cap
- 146.56M
- Vol
- 581.16K
- Avg vol
- 969.63K
- EPS
- -1.36
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.43
- High
- 2.57
- Forward P/E
- -1.61
- Beta
- 1.79
- Short ratio
- 14.46
- Inst. own
- 51.11%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.22
- 200-d avg
- 2.74
- 1y target
- 26.40
Key statistics
- Market cap
- 176.75M
- Enterprise value
- -31.37M
- Trailing P/E
- 0.00
- Forward P/E
- -1.61
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.86
- EPS (TTM)
- -2.64
- Beta
- 1.79
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -20.31M
- Total cash
- 89.58M
- Total debt
- 4.98M
- Return on equity
- -45.91%
- Shares outstanding
- 34.32M
- Short % of float
- 17.65%
- 50-day average
- 3.22
- 200-day average
- 2.74
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 26.40 +964.5% upside
Now 2.48
- Target (low)
- 14.00
- Target (mean)
- 26.40
- Target (high)
- 50.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.54333.
Financials — quick view
TARA Revenue — quarterly 0
TARA Net income — quarterly -21.67M
TARA EPS — quarterly -0.36
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.50 | -0.50 | 0.00 | 0.00% |
| Aug 6, 2024 | Jun 1, 2024 | -0.82 | -0.45 | +0.37 | +45.12% |
| May 2, 2024 | Mar 1, 2024 | -0.99 | -0.97 | +0.02 | +2.02% |
| Mar 13, 2024 | Dec 1, 2023 | -1.03 | -0.90 | +0.13 | +12.62% |
| Nov 3, 2023 | Sep 1, 2023 | -1.10 | -0.87 | +0.23 | +20.91% |
| Aug 3, 2023 | Jun 1, 2023 | -0.97 | -1.00 | -0.03 | -3.09% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 6, 2024 | Guggenheim | reit | Buy | Buy |
| Dec 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 12, 2024 | Oppenheimer | main | Outperform | Outperform |
| Aug 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- protaratx.com
News
- Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
- Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Bank of America Corp DE Buys 430,014 Shares of Protara Therapeutics, Inc. $TARA
- Protara Therapeutics Q2 EPS $(0.36) Misses $(0.33) Estimate
- Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline
- Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Moderate Buy” from Brokerages
- What Makes Protara Therapeutics (TARA) a New Buy Stock
- ROYAL CARIBBEAN GROUP APPOINTS TARA BUNCH TO BOARD OF DIRECTORS
- Tradeweb Launches TARA, an AI-Powered Research Assistant for Institutional Credit Trading
- Protara Therapeutics Enters $100M At-the-Market Equity Sales Agreement With TD Cowen
Your note
Sign in to keep a note on TARA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BANDARI JATHIN | Officer | Stock Award(Grant) | Jan 18, 2024 | 56,704 |
| FABBIO PATRICK | Chief Financial Officer | Stock Award(Grant) | Jan 18, 2024 | 22,000 |
| FRY HANNAH | Officer | Stock Award(Grant) | Jan 18, 2024 | 29,836 |
| OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Sep 11, 2024 | 0 |
| SHEFFERMAN JESSE M | Chief Executive Officer | Stock Gift | Aug 27, 2024 | 935,501 |
| ZUMMO JACQUELINE | Officer | Stock Award(Grant) | Jan 18, 2024 | 104,296 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 9.21% | 1,900,000 | 9.79M | Sep 29, 2024 |
| Opaleye Management Inc. | 8.15% | 1,681,154 | 8.66M | Sep 29, 2024 |
| Stempoint Capital LP | 4.57% | 942,857 | 4.86M | Sep 29, 2024 |
| Woodline Partners LP | 4.13% | 851,567 | 4.39M | Sep 29, 2024 |
| Boxer Capital, LLC | 3.93% | 811,627 | 4.18M | Sep 29, 2024 |
| Vanguard Group Inc | 3.68% | 759,612 | 3.91M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.99% | 616,301 | 3.17M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.68% | 140,668 | 724.44K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.47% | 97,351 | 501.36K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.24% | 49,200 | 253.38K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.20% | 41,236 | 212.37K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 30,335 | 156.22K | Oct 30, 2024 |